Slate Medicines announced that the first participant has been dosed in its Phase 1 clinical trial evaluating SLTE-1009, a therapy designed to expand treatment options for patients with advanced solid tumors. The milestone comes as Slate prepares to merge with Fulcrum Therapeutics (FULC), after which the combined company will trade under the ticker symbol SLTE.
Fulcrum Therapeutics, Inc. (FULC) and Slate Medicines, Inc. announced that they have entered into a definitive all-stock merger agreement to form a combined company focused on next-generation migraine therapies.
Fulcrum Therapeutics, Inc. (FULC), a clinical-stage biopharmaceutical company, announced the discontinuation of its lead Pociredir program for the treatment of sickle cell disease (SCD) following FDA's feedback regarding the implications of secondary malignancies observed with Tazverik, another therapy...
Fulcrum Therapeutics, Inc. (FULC) a clinical-stage biopharmaceutical company on Tuesday reported financial results for the fourth quarter and full year 2025, posting a widened net loss. In addition, the firm announced positive 12-week results from the 20 mg dose cohort of the Phase 1b PIONEER trial of...
Biotech stocks are experiencing substantial moves in pre-market activity on Monday, indicating potential trading opportunities. By evaluating sentiment and momentum before the bell, pre-market analysis becomes a foundational step in any trader's pre-market routine. In the Green - Pre-market Gainers On...
August 13, 2026 05:33 ET The World Health Organization’s cancer research agency, the International Agency for Research on Cancer (IARC), has classified three widely used medicines as carcinogenic to humans.